Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia
- PMID: 22956446
- PMCID: PMC3614140
- DOI: 10.1007/s11606-012-2211-5
Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia
Abstract
Background: Use of proton pump inhibitors (PPIs) is associated with community-acquired pneumonia (CAP), an association which may be confounded by unobserved patient and prescriber characteristics.
Objective: We assessed for confounding in the association between PPI use and CAP by using a 'falsification approach,' which estimated whether PPI use is also implausibly associated with other common medical conditions for which no known pathophysiologic link exists.
Design: Retrospective claims-based cohort study.
Setting: Six private U.S. health plans.
Subjects: Individuals who filled at least one prescription for a PPI (N = 26,436) and those who never did (N = 28,054) over 11 years.
Interventions: Multivariate linear regression of the association between a filled prescription for a PPI and a diagnosis of CAP in each 3-month quarter. In falsification analyses, we tested for implausible associations between PPI use in each quarter and rates of osteoarthritis, chest pain, urinary tract infection (UTI), deep venous thrombosis (DVT), skin infection, and rheumatoid arthritis. Independent variables included an indicator for whether a prescription for a PPI was filled in a given quarter, and quarterly indicators for various co-morbidities, age, income, geographic location, and marital status.
Key results: Compared to nonusers, those ever using a PPI had higher adjusted rates of CAP in quarters in which no prescription was filled (68 vs. 61 cases per 10,000 persons, p < 0.001). Similar associations were noted for all conditions (e.g. chest pain, 336 vs. 282 cases, p < 0.001; UTI, 151 vs. 139 cases, p < 0.001). Among those ever using a PPI, quarters in which a prescription was filled were associated with higher adjusted rates of CAP (111 vs. 68 cases per 10,000, p < 0.001) and all other conditions (e.g. chest pain, 597 vs. 336 cases, p < 0.001; UTI, 186 vs. 151 cases, p < 0.001), compared to quarters in which no prescription was filled.
Conclusion: PPI use is associated with CAP, but also implausibly associated with common medical conditions. Observed associations between PPI use and CAP may be confounded.
Figures
Comment in
-
Community-acquired pneumonia and proton pump inhibitors.J Gen Intern Med. 2013 Jul;28(7):874-5. doi: 10.1007/s11606-013-2430-4. J Gen Intern Med. 2013. PMID: 23549958 Free PMC article. No abstract available.
-
Community-acquired pneumonia and proton pump inhibitors.J Gen Intern Med. 2013 Jul;28(7):873. doi: 10.1007/s11606-013-2431-3. J Gen Intern Med. 2013. PMID: 23553432 Free PMC article. No abstract available.
-
Community-acquired pneumonia and proton pump inhibitors.J Gen Intern Med. 2013 Jul;28(7):872. doi: 10.1007/s11606-013-2432-2. J Gen Intern Med. 2013. PMID: 23553433 Free PMC article. No abstract available.
Similar articles
-
Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed.Clin Infect Dis. 2012 Jan 1;54(1):33-42. doi: 10.1093/cid/cir767. Epub 2011 Nov 18. Clin Infect Dis. 2012. PMID: 22100573
-
Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia.Aliment Pharmacol Ther. 2012 Nov;36(10):941-9. doi: 10.1111/apt.12069. Epub 2012 Oct 3. Aliment Pharmacol Ther. 2012. PMID: 23034135
-
Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis.Expert Rev Clin Pharmacol. 2012 May;5(3):337-44. doi: 10.1586/ecp.12.20. Expert Rev Clin Pharmacol. 2012. PMID: 22697595
-
Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis.PLoS One. 2015 Jun 4;10(6):e0128004. doi: 10.1371/journal.pone.0128004. eCollection 2015. PLoS One. 2015. PMID: 26042842 Free PMC article. Review.
-
What is the long term acid inhibitor treatment in gastroesophageal reflux disease? What are the potential problems related to long term acid inhibitor treatment in gastroesophageal reflux disease? How should these cases be followed?Turk J Gastroenterol. 2017 Dec;28(Suppl 1):S57-S60. doi: 10.5152/tjg.2017.15. Turk J Gastroenterol. 2017. PMID: 29199170 Review.
Cited by
-
Nonvitamin K Anticoagulants: Risk of Bleeding When Interacting With Other Medications: A Cohort Study From Medicare.Clin Cardiol. 2024 Oct;47(10):e70023. doi: 10.1002/clc.70023. Clin Cardiol. 2024. PMID: 39360666 Free PMC article.
-
Analysis of Risk Factors for Febrile Neutropenia in Patients with Small-Cell Lung Cancer Receiving Carboplatin Plus Etoposide Therapy.Oncology. 2024;102(7):565-573. doi: 10.1159/000535822. Epub 2023 Dec 29. Oncology. 2024. PMID: 38160673 Free PMC article.
-
Proton pump inhibitor use: systematic review of global trends and practices.Eur J Clin Pharmacol. 2023 Sep;79(9):1159-1172. doi: 10.1007/s00228-023-03534-z. Epub 2023 Jul 7. Eur J Clin Pharmacol. 2023. PMID: 37420019 Free PMC article. Review.
-
Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study.J Gastroenterol. 2023 Aug;58(8):734-740. doi: 10.1007/s00535-023-02007-5. Epub 2023 Jun 14. J Gastroenterol. 2023. PMID: 37314495 Free PMC article.
-
Pre-existing Proton Pump Inhibitor Treatment and Short-Term Prognosis of Acute Myocardial Infarction Patients.Front Cardiovasc Med. 2022 Jul 4;9:919716. doi: 10.3389/fcvm.2022.919716. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35859584 Free PMC article.
References
-
- Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391–398. - PubMed
-
- Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med. 1973;78(2):271–276. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
